Table 3 Comparison of characteristics between BM+ patients on 30 mg and 40 mg starting dose. Comparing the clinical characteristics of patients with brain metastases who started on 30 mg OD vs 40 mg OD of afatinib
From: Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases
Characteristic | Starting dose 30 mg, n (%) | Starting dose 40 mg, n (%) | p-value |
|---|---|---|---|
Age at diagnosis, years | |||
Median (range) | 62 (47–78) | 58 (26–76) | 0.299 |
< 65 | 15 (60.0) | 12 (70.6) | 0.482 |
≥ 65 | 10 (40.0) | 5 (29.4) | |
Sex | |||
Female | 16 (64.0) | 6 (35.3) | 0.067 |
Male | 9 (36.0) | 11 (64.7) | |
ECOG at start of afatinib | |||
0–1 | 20 (80.0) | 14 (82.4) | 1.000 |
2–3 | 5 (20.0) | 3 (17.6) | |
Smoking history | |||
Never | 18 (72.0) | 13 (76.5) | 1.000 |
Former/Current | 7 (28.0) | 4 (23.5) | |
Brain RT pre-afatinib | |||
Yes | 12 (48.0) | 14 (82.4) | 0.024 |
No | 13 (52.0) | 3 (17.6) | |
Brain RT post-afatinib | |||
Yes | 4 (16.0) | 3 (17.6) | 1.000 |
No | 21 (84.0) | 14 (82.4) | |
EGFR mutation type | |||
Exon 19 deletion | 15 (62.5) | 9 (52.9) | 0.019 |
Exon 20 insertion | 1 (4.2) | 0 | |
Exon 21 L858R | 3 (12.5) | 8 (47.1) | |
Double mutation | 5 (20.8) | 0 | |
Unknown | 1 | 0 | |
Site of progressiona | |||
CNS | 7 (63.6) | 3 (30.0) | 0.198 |
Systemic | 4 (36.4) | 7 (70.0) | |
No PD / unknown: | |||
Still on afatinib | 5 | 2 | |
Went on 2nd line | 3 | 4 | |
No scans / no PD recorded | 4 | 1 | |
FU at other hospital | 2 | 0 | |
Afatinib dose at PD, mg | |||
20 | 2 (18.2) | 1 (10.0) | 0.270 |
30 | 9 (81.8) | 6 (60.0) | |
40 | 0 | 3 (30.0) | |
No PD / unknown | 14 | 7 | |